文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters.

作者信息

Strohl William R

机构信息

Janssen BioTherapeutics, Janssen Research and Development, LLC, Pharmaceutical Companies of Johnson & Johnson, SH31-21757, 1400 Welsh and McKean Roads, PO Box 776, Spring House, PA, 19477, USA,

出版信息

BioDrugs. 2015 Aug;29(4):215-39. doi: 10.1007/s40259-015-0133-6.

DOI:10.1007/s40259-015-0133-6
PMID:26177629
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4562006/
Abstract

The purpose of making a "biobetter" biologic is to improve on the salient characteristics of a known biologic for which there is, minimally, clinical proof of concept or, maximally, marketed product data. There already are several examples in which second-generation or biobetter biologics have been generated by improving the pharmacokinetic properties of an innovative drug, including Neulasta(®) [a PEGylated, longer-half-life version of Neupogen(®) (filgrastim)] and Aranesp(®) [a longer-half-life version of Epogen(®) (epoetin-α)]. This review describes the use of protein fusion technologies such as Fc fusion proteins, fusion to human serum albumin, fusion to carboxy-terminal peptide, and other polypeptide fusion approaches to make biobetter drugs with more desirable pharmacokinetic profiles.

摘要

相似文献

[1]
Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters.

BioDrugs. 2015-8

[2]
Improving the pharmacokinetic properties of biologics by fusion to an anti-HSA shark VNAR domain.

MAbs. 2012

[3]
N-glycans of complex glycosylated biopharmaceuticals and their impact on protein clearance.

Eur J Pharm Biopharm. 2019-3-21

[4]
Half-life extension using serum albumin-binding DARPin® domains.

Protein Eng Des Sel. 2017-9-1

[5]
Intact bioactivities and improved pharmacokinetic of the SL335-IFN-β-1a fusion protein that created by genetic fusion of SL335, a human anti-serum albumin fab, and human interferon-β.

Immunol Lett. 2019-1-23

[6]
Albumin-binding domain extends half-life of glucagon-like peptide-1.

Eur J Pharmacol. 2021-1-5

[7]
Prospects of PASylation® for the design of protein and peptide therapeutics with extended half-life and enhanced action.

Bioorg Med Chem. 2017-9-15

[8]
Comparison of the pharmacokinetic and pharmacodynamic profiles of one US-marketed and two European-marketed epoetin alfas: a randomized prospective study.

Drugs R D. 2011

[9]
Receptor-Fc fusion therapeutics, traps, and MIMETIBODY technology.

Curr Opin Biotechnol. 2009-11-4

[10]
Albumin-binding domain from Streptococcus zooepidemicus protein Zag as a novel strategy to improve the half-life of therapeutic proteins.

J Biotechnol. 2017-7-10

引用本文的文献

[1]
A long-lasting prolactin stimulates galactopoiesis in mice.

iScience. 2025-7-15

[2]
Exploring glycoform-dependent dynamic modulations in human immunoglobulin G via computational and experimental approaches.

Proc Natl Acad Sci U S A. 2025-8-12

[3]
Novel loop structure of human IgG1 Fc fused CD38 targeted bispecific antibodies and their anti-tumor effect in acute myeloid leukemia.

J Transl Med. 2025-7-28

[4]
Advances in Peptidomimetics for Next-Generation Therapeutics: Strategies, Modifications, and Applications.

Chem Rev. 2025-8-13

[5]
Engineered IL-18 variants with half-life extension and improved stability for cancer immunotherapy.

J Immunother Cancer. 2025-7-15

[6]
Identification of a direct interaction between the Fab domains of IgG antibodies and human FcRn upon IgG-FcRn complex formation.

Commun Biol. 2025-6-12

[7]
Engineering of long-acting human growth hormone-Fc fusion proteins: Effects of valency, fusion position, and linker design on pharmacokinetics and efficacy.

PLoS One. 2025-5-15

[8]
Targeting the complement lectin pathway with a highly specific MASP-2 inhibitor protects against renal ischemia-reperfusion injury.

Proc Natl Acad Sci U S A. 2025-4-22

[9]
An ACE2-Fc decoy produced in glycoengineered plants neutralizes ancestral and newly emerging SARS-CoV-2 variants and demonstrates therapeutic efficacy in hamsters.

Sci Rep. 2025-4-2

[10]
Design of a novel long-acting insulin analogs by acetylation modification and compared with insulin Icodec.

Sci Rep. 2025-3-19

本文引用的文献

[1]
Chimeric fusion proteins used for therapy: indications, mechanisms, and safety.

Drug Saf. 2015-5

[2]
Reductions in synaptic proteins and selective alteration of prepulse inhibition in male C57BL/6 mice after postnatal administration of a VIP receptor (VIPR2) agonist.

Psychopharmacology (Berl). 2015-6

[3]
Fc fusion as a platform technology: potential for modulating immunogenicity.

Trends Biotechnol. 2014-12-6

[4]
The effects of fusion structure on the expression and bioactivity of human brain natriuretic peptide (BNP) albumin fusion proteins.

Curr Pharm Biotechnol. 2014

[5]
Half-life extension technologies for haemostatic agents.

Thromb Haemost. 2015-1

[6]
GSK2374697, a novel albumin-binding domain antibody (AlbudAb), extends systemic exposure of exendin-4: first study in humans--PK/PD and safety.

Clin Pharmacol Ther. 2014-9-19

[7]
Enhanced in vivo efficacy of a type I interferon superagonist with extended plasma half-life in a mouse model of multiple sclerosis.

J Biol Chem. 2014-10-17

[8]
Fusion of a short peptide that binds immunoglobulin G to a recombinant protein substantially increases its plasma half-life in mice.

PLoS One. 2014-7-24

[9]
Characterisation of a novel Fc conjugate of macrophage colony-stimulating factor.

Mol Ther. 2014-9

[10]
Co-opting biology to deliver drugs.

Biotechnol Bioeng. 2014-9

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索